Desentum has been awarded a 1.9 M€ grant from the EIC pilot SME Instrument for a project titled AllergyVAX. The two-and-a-half-year project, starting at the end of 2018, includes early clinical trials of Desentum’s lead product candidate, an immunotherapeutic vaccine for birch pollen allergy.Read more »
Below you can find the latest news releases from Desentum.
Desentum is progressing towards clinical stage with its first immunotherapeutic product targeting birch pollen allergy. It has raised approx. EUR 2.3 million in a crowd funding campaign arranged by a Finnish investment service company Kansalaisrahoitus. The funds raised in this round will be used...Read more »
Desentum is approaching first-in-man clinical trials with its lead product candidate, a modified hypoallergen aimed for an immunotherapeutic treatment of birch pollen allergy.Read more »
The annual congress of the European Academy of Allergy and Clinical Immunology will be in Helsinki in June 17-21. Desentum has presentations in two Oral Abstract Sessions.Read more »
Desentum secured funding to advance their treatment targeting birch pollen allergy.Read more »